GEHC

Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agents A manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol's clinical development under FDA Fast Track designation The program demonstrates GE HealthCare's commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (NASDAQ:GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic

The expanded collaboration builds on the companies' existing joint initiative by bringing to market enhanced capabilities of DeepHealth's new AI-powered Breast Suite, including ProFound Pro and Safeguard Review GE HealthCare to feature latest technologies to help ensure optimized breast care outcomes across mammography and ultrasound at SBI's 2026 Breast Cancer Imaging Symposium GE HealthCare (NASDAQ:GEHC) today announced an expanded collaboration with DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ:RDNT), to further the innovation, commercialization, and adoption of advanced AI-powered mammography tools. The an

VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The American heart care market is undergoing a structural shift that most retail investors haven't noticed yet. The U.S. cardiovascular devices sector is on track to nearly double, from $22.08 billion in 2025 to $41.29 billion by 2032, fueled by aging demographics and a wave of next-generation diagnostic platforms[1]. At the same time, 75% of U.S. health systems are now rolling out AI-powered clinical tools, with cardiac imaging and documentation leading the charge[2]. That convergence of hardware growth and software integration is creating asymmetric upside for companies building the infra

bkActiv provides real-time visualization and now offers digital integration with the Stealth AXiS surgical navigation system, together bringing planning, navigation and robotics into a unified workflow Digital integration designed to help neurosurgeons assess anatomy in real-time and support surgical precision and clinical confidence Collaboration builds on existing strategic alliance between GE HealthCare and Medtronic to accelerate next-generation technology innovation across the enterprise GE HealthCare today announced a digital integration between the GE HealthCare bkActiv™ intraoperative ultrasound (iUS) system and the Medtronic Stealth AXiS™ surgical navigation system, which

GE HealthCare (NASDAQ:GEHC) will announce its first quarter 2026 financial results before the market opens on Wednesday, April 29, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutic

GE HealthCare Technologies Inc. (NASDAQ:GEHC) (the "Company" or "GE HealthCare") announced today that it received notice on March 30, 2026, of an unsolicited "mini-tender" offer by Potemkin Limited to purchase up to 100,000 shares of GE HealthCare common stock at a price of $45.80 per share in cash. Potemkin Limited's offer price of $45.80 per share is approximately 34.80 percent lower than the $70.25 closing per share price of GE HealthCare's common stock on March 18, 2026, the last trading day before the mini-tender offer appears to have commenced. GE HealthCare does not endorse Potemkin Limited's unsolicited mini-tender offer and recommends that stockholders do not tender their shares

ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER,BC, March 27, 2026 /CNW/ -- USANewsGroup.com News Commentary – Heart disease is a quiet crisis that is draining healthcare resources worldwide, currently costing the European Union over €282 billion annually while tragically claiming 1.7 million lives a year[1]. This immense structural pressure is acting as a catalyst for smart money, with institutional capital rapidly accumulating positions in scalable, AI-enabled diagnostic platforms. In fact, peer-reviewed data now confirms that AI-driven healthcare startups command the largest share of venture funding in the entire biopharmaceutical sector[2]. At the center of this pivotal transit

SCHEDULE 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

COMPASS is one of the largest public‑private partnerships under the European Union's (EU) Innovative Health Initiative (IHI). The consortium aims to advance early detection and prediction of cardiotoxicity in cancer patients and cancer survivors. The initiative will leverage AI, advanced imaging, biomarkers, and integrated care pathways. GE HealthCare (NASDAQ:GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a t

The company will highlight the newly U.S. FDA 510(k) cleared Photonova Spectra photon-counting CT system, ReadyFix fleet management solution enabled to work with MAC VU360 resting ECG workstations, and a new collaboration to advance interventional cardiology At ACC.26, GE HealthCare (NASDAQ:GEHC) will showcase some of its boldest ideas yet that support clinicians across the cardiology care pathway - from diagnosis to treatment to procedural guidance and monitoring. Its latest cardiology innovations, featuring advancements within diagnostic cardiology, CT, image guiding solutions, ultrasound, cloud, and software solutions, are helping clinicians deliver critical precision care throughout

FDA clearance quickly follows Photonova Spectra's debut at the Radiological Society of North America (RSNA) 2025 Annual Meeting, marking rapid momentum for GE HealthCare's innovative photon-counting CT technology Photonova Spectra introduces the next generation of spectral photon-counting CT technology with 8‑bin energy resolution, powered by GE HealthCare's proprietary Deep Silicon detector technology and a one‑scan universal workflow designed to boost efficiency and reduce complexity across a wide range of CT exams Photonova Spectra is a result of the company's $5.1 billion innovation investment, leading to a wave of transformational products across the portfolio which combined are

DEFA14A - GE HealthCare Technologies Inc. (0001932393) (Filer)

DEF 14A - GE HealthCare Technologies Inc. (0001932393) (Filer)

Expands GE HealthCare's enterprise imaging footprint by delivering comprehensive, end‑to‑end solutions across ambulatory, teleradiology, and hospital care settings Advances GE HealthCare's D3 strategy by accelerating the development of disease‑focused smart devices and solutions enabled by digital (cloud and software) and artificial intelligence (AI) capabilities Enhances a fully connected, cloud‑first imaging ecosystem with an expanded GE HealthCare portfolio of AI, digital tools, and SaaS offerings designed to improve clinical operations Tuck‑in acquisition expected to strengthen the Imaging portfolio, increase recurring revenue mix, and support sustainable top‑line growth and p

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

3 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

GE HealthCare (NASDAQ:GEHC) announced today the appointment of Kevin A. Lobo, Chair and Chief Executive Officer of Stryker Corporation (NYSE:SYK), to its Board of Directors effective March 13. Mr. Lobo brings more than 25 years of medical technology, operational, and financial leadership experience. His clinical expertise and track record of driving innovation and scaling global businesses make him well qualified to contribute to GE HealthCare's strategic priorities. "Kevin is a seasoned healthcare executive with a deep understanding of the medical technology landscape. His knowledge and insight will further strengthen our Board as we continue to build a more personalized, connected and s

Built for the demands of modern imaging, View streamlines workflows, and helps enhance patient care as the advanced diagnostic viewer powering the Genesis Radiology Workspace GE HealthCare today announced that View, the powerful viewer within the Genesis™ Radiology Workspace, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Designed as a fast, diagnostic, zero‑footprint viewer, View serves as the core anchor of the Genesis Radiology Workspace.2 This next‑generation solution aims to transform radiology workflows, unify the user experience, and empower radiologists with greater efficiency and precision. Studies show that radiologists spend up to 44% of the

Booth #2525 will highlight the company's AI-powered, cloud-first and software solutions intended to help teams access data and insights more efficiently GE HealthCare (NASDAQ:GEHC) will showcase innovations moving healthcare forward at the Health Information and Management Systems Society (HIMSS) Global Health Conference & Exhibition 2026 in Las Vegas from March 9-12, 2026. This year, GE HealthCare will spotlight meaningful technology transforming the way healthcare professionals approach patient care, from imaging operations and fleet management to enterprise solutions, ultrasound, and patient care technologies. The healthcare industry continues to confront worsening workforce gaps w

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)